Clinical Trials Search
A Phase II Study of Talimogene Laherparepvec (T-VEC) in the Treatment of Locally Advanced Cutaneous Angiosarcoma
This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.
Primary: To evaluate the efficacy of T-VEC as treatment for relapsed/refractory cutaneous angiosarcoma. Secondary: To establish duration of response among treated patients - To measure the rate of progression-free survival among treated patients - To measure the pathologic complete response (pCR) rate for lesions that have complete clinical regression following study treatment - To monitor adverse events following administration of T-VEC injections - To measure the rate of patients requiring surgical resection of T-VEC treated lesions - To measure the degree of immune infiltration in surgically resected T-VEC treated tumors
Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec)